About Graham DyerThis author has not yet filled in any details.
So far Graham Dyer has created 0 blog entries.
Yes, I understand that I’m now leaving KidneyIntelX.com and going to Renalytix.com to read the Well Filtered™ blog.
Yes! Sign me up so that I can be one of the first to:
Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.
You are now subscribed to Well Filtered. We’ll be in touch soon.
Renalytix is seeking FDA De Novo marketing authorization for KidneyIntelX. The test is not FDA approved nor cleared for any use at this time. KidneyIntelX yields a custom risk score that identifies which adult diabetic patients in early stages of chronic kidney disease are at low, intermediate or high risk for rapid progressive decline in kidney function within a period of up to five years. To report a product concern or suspected Adverse Event, please contact Renalytix Client Service at 1-888.203.2725.